Anti-D (WinRho SD) treatment of children with chronic autoimmune thrombocytopenic purpura stimulates transient cytokine/chemokine production.

@article{Semple2002AntiDS,
  title={Anti-D (WinRho SD) treatment of children with chronic autoimmune thrombocytopenic purpura stimulates transient cytokine/chemokine production.},
  author={John W Semple and Darlene T Allen and Mark Rutherford and Michael Woloski and Marianna D{\'a}vid and Cindy D Wakefield and Sheila E Butchart and John T. Freedman and Victor S. Blanchette},
  journal={American journal of hematology},
  year={2002},
  volume={69 3},
  pages={225-7}
}
Intravenous anti-D is often used in the treatment of autoimmune thrombocytopenic purpura (AITP), but little is known about its mechanisms of action. To investigate anti-D's potential in vivo mechanism(s) of action, a small group (N = 7) of children with chronic AITP was studied. The children initially received either 25 or 50 microg/kg of WinRho-SD in a four-cycle cross-over trial, and peripheral blood samples from the first and third cycles were assessed for cytokine levels at pre-treatment, 3… CONTINUE READING